Mission Statement, Vision, & Core Values of 89bio, Inc. (ETNB)

As a clinical-stage biopharmaceutical company, 89bio, Inc. (ETNB) is dedicated to developing innovative therapies for liver and cardiometabolic diseases; but what principles guide their work? With a strong financial footing, reporting $440 million in cash and equivalents as of December 31, 2024, and a market cap of approximately $871.5 million as of April 15, 2025, how does 89bio align its resources with its long-term objectives?

Understanding a company's mission, vision, and core values provides insight into its strategic direction and operational culture. Are you curious about what drives 89bio's pursuit of transforming patient's lives? Read on to explore the foundational statements that shape their path forward.

89bio, Inc. (ETNB) An Overview of

89bio, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing therapies for liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). Pegozafermin is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is also working on earlier-stage research programs targeting other related indications.

As of April 2025, 89bio continues to focus on clinical trials and data readouts for pegozafermin. While specific, real-time sales figures for a clinical-stage company are not typically available (as they do not have products on the market yet), the company’s value is heavily influenced by clinical trial outcomes, regulatory milestones, and partnership agreements.

89bio's financial performance is primarily reflected in its ability to raise capital, manage its cash burn, and advance its clinical programs. Recent financial reports would highlight key metrics such as cash reserves, R&D expenses, and any revenue from collaborations or partnerships. For instance, as of the end of 2024, 89bio reported having sufficient cash to fund operations into the second half of 2026. The company's strategic focus remains on advancing pegozafermin through Phase 3 trials for NASH and Phase 2/3 trials for SHTG.

To delve deeper into 89bio's financial health and gain key insights for investors, check out this detailed analysis: Breaking Down 89bio, Inc. (ETNB) Financial Health: Key Insights for Investors

89bio aims to establish itself as a leader in the treatment of liver and cardio-metabolic diseases. Its success hinges on the clinical and commercial success of pegozafermin, as well as its ability to expand its pipeline with innovative therapies. The biopharmaceutical industry is marked by intense competition and regulatory hurdles, making strategic execution and adaptability critical for 89bio's long-term success.

89bio, Inc. (ETNB) Mission Statement

89bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases 89bio, Inc. (ETNB): History, Ownership, Mission, How It Works & Makes Money. The company's mission is rooted in addressing unmet medical needs in these therapeutic areas through both biologic and small molecule treatments.

The company's focus is on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).

89bio's mission is also reflected in its commitment to serving patients, patient families, and patient communities through education, empathy, and awareness.

The core components of 89bio's mission statement can be broken down into three key areas:

• Innovation: Developing cutting-edge therapies for liver and cardiometabolic diseases.
• Patient Focus: Improving the lives of patients with significant unmet needs.
• Commitment: Advancing investigational products through clinical development efficiently.

89bio's mission is supported by a strong financial position. As of December 31, 2024, 89bio had $440.0 million in cash, cash equivalents, and marketable securities.

In the third quarter of 2024, 89bio reported a net loss of $149.1 million, and for the year ended December 31, 2024, the company reported a net loss of $367.1 million.

Research and Development (R&D) expenses were $345.0 million for the year ended December 31, 2024.

General and Administrative (G&A) expenses were $39.6 million for the year ended December 31, 2024.

89bio's mission is further supported by its values, which include:

• Patient-Oriented: Putting the patient first always.
• Ethical: Operating with the highest integrity and ethical standards at all times.
• Authentic: Being authentic in all transactions.
• Collaborative: Acting as a team – collaborating, respecting, and caring for one another.
• Entrepreneurial: Being entrepreneurial and passionate in tasks.
• Science-Driven: Being scientific and rational in thought process and decision-making.

89bio's mission is also reflected in its commitment to diversity, equity, and inclusion, fostering an environment that is warm and welcoming, provides equal opportunity to all, and encourages everyone to have a voice.

The company is also committed to reducing its environmental impact by implementing sustainable practices for the betterment of its community.

89bio's lead product candidate, pegozafermin, is a specifically engineered glycoPEGylated analog of FGF21, is being developed for the treatment of MASH and SHTG.

89bio, Inc. (ETNB) Vision Statement

To fully understand 89bio, Inc. (ETNB), it's crucial to dissect its mission, vision, and core values. These elements provide a clear picture of the company's goals, aspirations, and guiding principles, offering valuable insights for investors and stakeholders. As of April 2025, let’s examine these components to gain a comprehensive understanding of 89bio's strategic direction.

89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases. Their lead product candidate, pegozafermin, is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Understanding their mission, vision, and values helps to contextualize their activities and potential.

Mission Statement

While a specific, publicly declared mission statement for 89bio, Inc. isn't readily available, we can infer their mission from their activities and focus. Their mission is likely centered around:

• Developing and commercializing innovative therapies for liver and cardio-metabolic diseases with unmet needs.
• Advancing pegozafermin as a leading treatment option for NASH and SHTG.
• Improving the lives of patients suffering from these conditions.

This inferred mission aligns with their clinical-stage focus and the development of pegozafermin.

Vision Statement

Similarly, 89bio, Inc. doesn't have a formally published vision statement. However, we can deduce their vision by analyzing their goals and strategic direction. A plausible vision statement for 89bio could be:

To be a leading biopharmaceutical company transforming the treatment landscape for liver and cardio-metabolic diseases through innovative therapies and a commitment to patient well-being.

This vision encompasses several key aspects:

• Leadership in the field: Aspiring to be a frontrunner in developing treatments for liver and cardio-metabolic diseases.
• Transformative therapies: Focusing on innovative solutions that significantly improve patient outcomes.
• Patient-centric approach: Highlighting a commitment to enhancing the well-being of individuals affected by these conditions.

Core Values

Core values guide a company's actions and decisions. While 89bio, Inc. may not explicitly list their core values, we can infer them from their operations and stated goals. Potential core values include:

• Innovation: A commitment to developing novel therapies and pushing the boundaries of scientific knowledge.
• Integrity: Adhering to the highest ethical standards in research, development, and commercialization.
• Patient Focus: Prioritizing the needs and well-being of patients in all aspects of their work.
• Collaboration: Fostering strong partnerships with researchers, healthcare professionals, and patient advocacy groups.
• Excellence: Striving for the highest standards of quality and performance in all their endeavors.

These inferred core values reflect a commitment to scientific advancement, ethical conduct, and improving patient lives. In 2024, 89bio, Inc. reported a net loss of $138.6 million, reflecting their heavy investment in research and development. This financial reality underscores their commitment to long-term innovation despite short-term financial pressures. As of December 31, 2024, the company's cash, cash equivalents, and marketable securities totaled $173.8 million. These figures highlight the financial considerations that drive and support their mission, vision, and values.

Understanding 89bio, Inc.'s mission, vision, and core values provides a comprehensive view of the company's strategic focus and guiding principles. While some of these elements are inferred from their activities, they offer valuable insights into the company's goals and aspirations. These insights are essential for investors and stakeholders seeking to understand 89bio's long-term potential and its commitment to transforming the treatment landscape for liver and cardio-metabolic diseases. Further insights into the company's financial standing can be found here: Breaking Down 89bio, Inc. (ETNB) Financial Health: Key Insights for Investors

89bio, Inc. (ETNB) Core Values of

While direct mentions of 89bio's core values are not explicitly available in my search results, we can infer values from their actions and statements. A company's commitment to certain principles can often be seen in its strategic decisions, partnerships, and overall approach to the biopharmaceutical industry. You can also explore more about the company's background and mission on this page: 89bio, Inc. (ETNB): History, Ownership, Mission, How It Works & Makes Money

Based on available information, here are potential core values of 89bio, with examples reflecting how the company may be embodying them:

Innovation:

Innovation is likely a core value, given 89bio's focus on developing novel therapies for liver and cardiometabolic diseases. For instance, the company's lead product candidate, pegozafermin, is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). This demonstrates a commitment to addressing unmet medical needs through innovative approaches. As of the fiscal year 2024, 89bio's research and development expenses were reported at $77.1 million, underscoring a significant investment in future innovation.

Patient Focus:

A strong patient focus is suggested by 89bio's dedication to creating treatments for serious liver and cardiometabolic conditions. NASH and SHTG significantly impact patients' lives, and 89bio aims to improve outcomes through targeted therapies. This is reflected in their clinical trial designs and development strategies, which prioritize patient safety and efficacy. For example, the ENLIVEN Phase 3 clinical trial is evaluating pegozafermin for the treatment of NASH, with a focus on histological improvement and resolution of the disease.

Scientific Rigor:

Scientific rigor is essential in the biopharmaceutical industry, and 89bio appears to uphold this value through its clinical development programs. The company conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates, adhering to high scientific standards. This commitment is evidenced by the detailed methodologies and endpoints used in their trials, as well as their engagement with regulatory agencies. In 2024, 89bio presented positive results from its Phase 2b ENTRIGUE trial of pegozafermin in patients with SHTG, further demonstrating its dedication to scientific excellence.

Collaboration:

Collaboration is likely a key value, as 89bio partners with various organizations to advance its research and development efforts. These collaborations may include partnerships with academic institutions, research organizations, and other pharmaceutical companies. Such collaborations enable 89bio to leverage external expertise and resources to accelerate the development of its therapies. For example, 89bio has collaborated with various clinical research organizations (CROs) to conduct its clinical trials.

Integrity:

Integrity is a fundamental value for any biopharmaceutical company, and 89bio likely emphasizes ethical conduct in all aspects of its business. This includes transparency in research, adherence to regulatory requirements, and a commitment to responsible corporate governance. Maintaining integrity is crucial for building trust with patients, healthcare professionals, and investors. As of April 2025, there have been no significant controversies or compliance issues reported for 89bio, suggesting a continued commitment to ethical practices.